Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012184 | 0.92 | CTSK (0.56) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL25029385 | 0.92 | CTSK (0.49) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL3370047 | 0.91 | CTSK (0.56) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL20985356 | 0.90 | CTSK (0.47) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL23689562 | 0.90 | CTSK (0.47) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL25032075 | 0.88 | CTSK (0.51) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL542675 | 0.88 | OPRM1 (0.55) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL7917248 | 0.88 | BTK (0.54) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| Acetic Acid SCHEMBL31327099 | 0.86 | CTSK (0.44) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL56856 | 0.86 | EPHX1 (0.53) | CTSKKCNA3BTKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-3466943-B1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO LTD (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-08-22 | — | — | US | disclosed |
| EP-3466943-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018018986-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 安润医药科技（苏州）有限公司 | 2018-02-01 | — | — | WO | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, CD2, TYRO3 | CTSK 2946/4885OPRM1 400/4885OPRD1 417/4885 |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | CTSK 1766/4885OPRM1 4429/4885OPRD1 4175/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CTSK 1766/4885OPRM1 4429/4885OPRD1 4175/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CTSK 1766/4885OPRM1 4429/4885OPRD1 4175/4885 |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ALK, CD2, TYRO3 | CTSK 2946/4885OPRM1 400/4885OPRD1 417/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | CTSK 845/4885OPRM1 642/4885OPRD1 667/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CTSK 1766/4885OPRM1 4429/4885OPRD1 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.